The Hong Kong Polytechnic University (PolyU) and the Chinese University of Hong Kong have made a major breakthrough in the joint research and development of new drugs. The team developed a new drug, ABarginase, which uses a novel pharmacological mechanism - arginine consumption.
The drug is suitable for a variety of metabolic diseases such as prediabetes, type II diabetes, non-alcoholic fatty liver disease, etc., and the pharmaceutical process is low cost and efficient, so that more patients can afford and benefit.